Mast cell leukemia

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

(2012) E. Soucie et al.   BLOOD

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor

(2012) Sophie Georgin-Lavialle et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Death from Mast Cell Leukemia: A Young Patient with Longstanding Cutaneous Mastocytosis Evolving into Fatal Mast Cell Leukemia

(2012) Rattanavalai Chantorn et al.   PEDIATRIC DERMATOLOGY

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib

(2011) Andrzej Mital et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

(2011) M S Spector et al.   LEUKEMIA

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis

(2011) C Teodosio et al.   LEUKEMIA

Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge

(2010) Angela R. Arredondo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

(2010) Carle Paul et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I treat patients with advanced systemic mastocytosis

(2010) P. Valent et al.   BLOOD

Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis

(2010) K. J. Aichberger et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes

(2010) Cristina Teodosio et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

(2009) K.-H. Lim et al.   BLOOD

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

(2009) K. J. Aichberger et al.   BLOOD

Successful Treatment of KIT D816V-positive, Imatinib-resistant Systemic Mastocytosis with Interferon-alpha

(2009) Chikamasa Yoshida et al.   INTERNAL MEDICINE

Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations

(2009) Christine Bodemer et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

Mast cell leukemia with rapidly progressing portal hypertension

(2009) Masayuki Yoshida et al.   PATHOLOGY INTERNATIONAL

Mast cell leukemia: a report of ten cases

(2008) Caterina Giovanna Valentini et al.   ANNALS OF HEMATOLOGY

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils

(2008) M. Kneidinger et al.   BLOOD

Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

Dasatinib therapy for systemic mastocytosis: four cases

(2008) Duncan Purtill et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion

(2008) I. Lahortiga et al.   HAEMATOLOGICA